I. Call to Order

II. Parliamentary Business
   A. Introduction of Members/Roll Call and DHH Staff
   B. Approval of April 30, 2014 Meeting Minutes
   C. Attendance/Additional Meetings

III. Ethics Reminders

IV. Managed Care Update

V. Reports
   A. Prior Authorization Monthly Report
   B. PDL Reflecting November 6, 2013 P&T Committee Recommendations
   C. Travel Regulations 2013-2014
   D. Louisiana Medicaid Preferred Drug List Program Overview and Results Report

VI. New Business
   A. Explanation of TOP$, Monographs and Cost Sheets
   B. Therapeutic Class Reviews/Drug Manufacturer Testimony
      1. Alzheimers Agents
      2. Antidepressants, Other
      3. Antidepressants, SSRIs
      4. Antihistamines, Minimally Sedating
      5. Antihypertensives, Sympatholytic
      6. Antihyperuricemics, Oral
      7. Antiparkinsons Agents
      8. Antipsoriatrics, Oral
      9. Antipsoriatrics, Topical
     10. Antipsychotics
     11. Anxiolytics
     12. Bile Salts
     13. Bronchodilators, Beta Agonist
     14. COPD Agents
     15. Cytokine And CAM Antagonists
     16. Emollients
     17. Glucocorticoids, Inhaled
     18. Histamine II receptor blockers
     19. Immunomodulators, Atopic Dermatitis
     20. Immunomodulators, Topical
     21. Intranasal Rhinitis Agents
     22. Leukotriene Modifiers
     23. Neuropathic Pain
24. NSAIDs
25. Ophthalmic Antibiotic/Steroid Combinations
26. Ophthalmic Antibiotics
27. Ophthalmics For Allergic Conjunctivitis
28. Ophthalmics, Anti-Inflammatories
29. Ophthalmics, Glaucoma Agents
30. Otic Anti-Infecives and Anesthetics
31. Otic Antibiotics
32. Sedative Hypnotics
33. Smoking Cessation
34. Steroids, Topical - High
35. Steroids, Topical - Low
36. Steroids, Topical - Medium
37. Steroids, Topical – Very High
38. Stimulants and Related Agents

VII. New Single Drug Reviews in Current PDL Categories…………………..Julie Pritchard
1. Analgesics Narcotics, Short - Xartemis XR
2. Antifungals, Topical – Jublia
3. Beta-Blockers – Hemangeol
4. Hypoglycemics, Incretin Mimetics and Enhancers - Bydureon Pens
5. Hypoglycemics, Incretin Mimetics and Enhancers – Tanzeum
6. Hypoglycemics, SGLT2 - Jardiance
7. Hypoglycemics, SGLT2 - Invokamet
8. Lincosamides – Sivextro
9. Opiate Dependence – Evzio
10. PAH Agents, Oral and Inhaled - Orenitram ER
11. Platelet Aggregation Inhibitors - Zontivity
12. Hepatitis C Agents - Harvoni

VIII. Other Business

VIII. Next Steps
A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

IX. Next Meeting Date – May 6, 2015

X. Public Testimony